Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies

Hepatology

Volumn 59, Issue 3, 2014, Pages 924-934

  Turtoi, Andrei ^a   Blomme, Arnaud ^a   Debois, Delphine ^a   Somja, Joan ^a   Delvaux, David ^a   Patsos, Georgios ^a   Di Valentin, Emmanuel ^a   Peulen, Olivier ^a   Mutijima, Eugène Nzaramba ^a   De Pauw, Edwin ^a   Delvenne, Philippe ^a   Detry, Olivier ^b   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER THERAPY; CARBOHYDRATE METABOLISM; CELL GROWTH; CELL MOTION; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; DNA REPAIR; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUTRIENT AVAILABILITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS; PROTEIN TARGETING;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84896706261     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26608     Document Type: Article

References (30)

1. Garattini L, van de Vooren K, Zaniboni A. Ethics for end-of-life treatments: metastatic colorectal cancer is one example. Health Policy 2012;109:97-103.
2. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487-493.
3. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-540.
4. Navin, N, Kendall J, Troge J, Andrews P, Rodgers L, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-94.
5. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-1117.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
7. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
8. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-3683.
9. Hoyer M, Swaminath A, Bydder S, Lock M, Mendez Romero A, Kavanagh B, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012;82:1047-1057.
10. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 1997;69:4751-4760.
11. Kang S, Kim MJ, An H, Kim BG, Choi YP, Kang KS, et al. Proteomic molecular portrait of interface zone in breast cancer. J Proteome Res 2009;9:5638-5646.
12. Kang S, Shim HS, Lee JS, Kim DS, Kim HY, Hong SH, et al. Molecular proteomics imaging of tumor interfaces by mass spectrometry. J Proteome Res 2010;9:1157-1164.
13. Turtoi A, Musmeci D, Wang Y, Dumont B, Somja J, Bevilacqua G, et al. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 2011;10:4302-4013.
14. Turtoi A, Dumont B, Greffe Y, Blomme A, Mazzucchelli G, Delvenne P, et al. Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious tissues. J Proteome Res 2011;10:3160-3182.
15. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 microarray software suite. Method Enzymol 2006;411:134-193.
16. McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des 2012;18:1784-1795.
17. Harris PJ, Speranza G, Dansky Ullmann C. Targeting embryonic signaling pathways in cancer therapy. Expert Opin Ther Targets 2012;16:131-145.
18. Binello E, Germano IM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol 2012;14:256-265.
19. Ping YF, Bian XW. Consice review: contribution of cancer stem cells to neovascularization. Stem Cells 2011;29:888-894.
20. Conrotto P, Roesli C, Rybak J, Kischel P, Waltregny D, Neri D, et al. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 2008;123:2856-2864.
21. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, et al. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008;99:1729-1734.
22. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004;23:1377-1391.
23. Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck FH, et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009;137:165-175.
24. Lin AY, Chua MS, Choi YL, Yeh W, Kim YH, Azzi R, et al. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One 2011;6:e16636.
25. Sun L, Hu H, Peng L, Zhou Z, Zhao X, Pan J, et al. P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol 2011;179:380-390.
26. Ween MP, Oehler MK, Ricciardelli C. Transforming growth factor-beta-induced protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci 2012;13:10461-10477.
27. Zhang Y, Wen G, Shao G, Wang C, Lin C, Fang H, et al. TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res 2009;69:37-44.
28. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, et al. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008;22:308-321.
29. Chan SH, Yee Ko JM, Chan KW, Chan YP, Tao Q, Hyytiainen M, et al. The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome. Int J Cancer 2011;129:565-573.
30. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123-131.